Compound News and Research

RSS

EB Pharma licenses tipifarnib from Janssen to study potential new therapy for HDV

EB Pharma, LLC., a subsidiary of Eiger BioPharmaceuticals, Inc., announced that it has executed an agreement with Janssen Pharmaceutica NV, for an exclusive license, to tipifarnib in the field of virology and a related, clinical stage back-up compound.

23 Dec 2014

Offspring of mice treated with drug had delayed onset, reduced symptoms of Huntington's disease

Famine, drug abuse and even stress can "silence" certain genes, causing health problems in generations to come. Now scientists are wondering—could therapies that change gene expression in parents help their children?

23 Dec 2014

Resveratrol activates ancient stress response in human cells, shows study

Scientists at The Scripps Research Institute (TSRI) have found that resveratrol, the red-wine ingredient once touted as an elixir of youth, powerfully activates an evolutionarily ancient stress response in human cells.

23 Dec 2014

SLU investigators find promising candidates for new herpes virus treatments

Saint Louis University research findings published in the December issue of Antimicrobial Agents and Chemotherapy report a family of molecules known as nucleotidyltransferase superfamily (NTS) enzyme inhibitors are promising candidates for new herpes virus treatments.

19 Dec 2014

MU researcher developing nano-scale molecules to image, treat different diseases

Nanomedicine is the medical application of nanotechnology, or the use of microscopic structures to diagnose, image, treat and prevent disease. Current problems in nanomedicine include understanding and anticipating the potentially toxic impact these nanostructures have on the body and the environment once they're released.

17 Dec 2014

Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

Novogen Limited, Australian/US biotechnology company, today announces that it has confirmed that its lead candidate product, TRXE-009, originally developed for the treatment of brain cancers, has been shown in pre-clinical studies also to be highly active against melanoma.

16 Dec 2014

Olympus BioScapes Digital Imaging Competition 2014 winners announced

From algae to zebrafish, life under the microscope can be beautiful, surprising and mysterious. This week, amazing glimpses of the unseen universe earned top prizes in the 2014 Olympus BioScapes Digital Imaging Competition®, the world’s foremost forum for showcasing microscope images of life science subjects.

From Evident Corporation - Life Sciences 16 Dec 2014

Survey reveals use of 'fake weed' among college students

A survey of more than 300 college students reveals that college students who use "fake weed" or synthetic THC are most likely to have tried the drug because they were curious. Rebecca Vidourek, a University of Cincinnati assistant professor of health promotion and assistant director of the Center for Prevention Science; Keith King, a UC professor of health promotion and director of the Center for Prevention Science; and Michelle Burbage, a graduate student and graduate assistant for UC's Health Promotion and Education Program, published their findings in the current issue of the Journal of Drug Education.

16 Dec 2014

FL118 agent shows efficacy as personalized, targeted therapy for certain cancer tumors

A team led by Fengzhi Li, PhD, and Xinjiang Wang, PhD, of Roswell Park Cancer Institute has reported new findings regarding therapeutic targets of the novel anticancer agent FL118. Previous studies from these researchers have showed that FL118 induces cancer cell death, or apoptosis, by inhibiting expression of multiple cell-survival proteins (survivin, Mcl-1, XIAP or cIAP2).

15 Dec 2014

Anavex Life Sciences qualifies to trade on OTCQX

OTC Markets Group Inc., operator of Open, Transparent and Connected financial marketplaces, today announced that Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS), and various types of cancer, has qualified to trade on OTCQX, the best marketplace for established, global and growth companies.

14 Dec 2014

Penn researchers find effective way to inhibit inflammatory response during kidney dialysis

Frequent kidney dialysis is essential for the approximately 350,000 end-stage renal disease (ESRD) patients in the United States. But it can also cause systemic inflammation, leading to complications such as cardiovascular disease and anemia, and patients who rely on the therapy have a five-year survival rate of only 35 percent. Such inflammation can be triggered when the complement cascade, part of the body's innate immune system, is inadvertently activated by modern polymer-based dialysis blood filters.

14 Dec 2014

MU's Jerry Atwood recognized as AAAS Fellow for contributions to chemistry research

Chemistry is a branch of physical science studying composition, structure and properties of matter. With decades of study and a deep understanding of the field, Jerry Atwood, a researcher at the University of Missouri, is a prolific chemist who has guided the study of molecules and how they interact in the physical world.

12 Dec 2014

Scientific collaboration reveals encouraging insight on AMD disease

Insilico Medicine along with scientists from Vision Genomics and Howard University shed light on AMD disease, introducing the opportunity for eventual diagnostic and treatment options.

12 Dec 2014

Researchers develop new method to track movement of carcinogenic PAHs in the human body

Researchers for the first time have developed a method to track through the human body the movement of polycyclic aromatic hydrocarbons, or PAHs, as extraordinarily tiny amounts of these potential carcinogens are biologically processed and eliminated.

11 Dec 2014

Scientists report new family of selective molecules to combat causal agent of malaria

Malaria is one of the most serious health problems worldwide, registering 200 million clinical cases and more than 600,000 attributable deaths per year, according to information from the World Health Organization in 2013. Given the emerging resistance to the standard treatment most widely used throughout the world, which is based on artemisinin and its analogs, there is a need for new antimalarial compounds.

11 Dec 2014

Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis

Bayer HealthCare and the Drugs for Neglected Diseases initiative (DNDi) have signed an agreement under which Bayer will provide the active ingredient emodepside to support DNDi in its effort to develop a new oral drug to treat river blindness (or onchocerciasis). The world's second leading infectious cause of blindness, river blindness is a neglected tropical disease caused by a filarial worm.

10 Dec 2014

Epizyme's PRMT5 inhibitor shows efficacy in pre-clinical models of mantle cell lymphoma

Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the results from a preclinical study showing in vitro and in vivo activity of its first-in-class PRMT5 inhibitor EPZ015666 in mantle cell lymphoma (MCL), an aggressive form of non-Hodgkin lymphoma (NHL).

10 Dec 2014

Agent THZ1 shrinks human-like small cell lung tumors in mice

Small cell lung cancer - a disease for which no new drugs have been approved for many years - has shown itself vulnerable to an agent that disables part of tumor cells' basic survival machinery, researchers at Dana-Farber Cancer Institute and the Massachusetts Institute of Technology reported.

9 Dec 2014

PRM-151 compound shows positive results for treating advanced myelofibrosis

A study that investigated the potential of the compound PRM-151 (PRM) for reducing progressive bone marrow fibrosis (scarring) in patients with advanced myelofibrosis has shown initial positive results. Myelofibrosis is a life-threatening bone marrow cancer.

8 Dec 2014

Studies presented at ASH meeting compare new, standard-of-care treatments for blood clots

Studies presented at the 56th American Society of Hematology Annual Meeting and Exposition compare new and standard-of-care treatments for blood clots and further illuminate clot risks in vulnerable populations, such as cancer patients.

8 Dec 2014

Compound News and Research

EB Pharma licenses tipifarnib from Janssen to study potential new therapy for HDV

Offspring of mice treated with drug had delayed onset, reduced symptoms of Huntington's disease

Resveratrol activates ancient stress response in human cells, shows study

SLU investigators find promising candidates for new herpes virus treatments

MU researcher developing nano-scale molecules to image, treat different diseases

Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

Olympus BioScapes Digital Imaging Competition 2014 winners announced

Survey reveals use of 'fake weed' among college students

FL118 agent shows efficacy as personalized, targeted therapy for certain cancer tumors

Anavex Life Sciences qualifies to trade on OTCQX

Penn researchers find effective way to inhibit inflammatory response during kidney dialysis

MU's Jerry Atwood recognized as AAAS Fellow for contributions to chemistry research

Scientific collaboration reveals encouraging insight on AMD disease

Researchers develop new method to track movement of carcinogenic PAHs in the human body

Scientists report new family of selective molecules to combat causal agent of malaria

Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis

Epizyme's PRMT5 inhibitor shows efficacy in pre-clinical models of mantle cell lymphoma

Agent THZ1 shrinks human-like small cell lung tumors in mice

PRM-151 compound shows positive results for treating advanced myelofibrosis

Studies presented at ASH meeting compare new, standard-of-care treatments for blood clots

Enhancing confidence in chemical ionization spectrometry data eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News